185 related articles for article (PubMed ID: 10195045)
1. Control of STDs--the role of prophylactic vaccines against herpes simplex virus.
Stanberry LR
Sex Transm Infect; 1998 Dec; 74(6):391-4. PubMed ID: 10195045
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
3. Development of prophylactic vaccines for genital and neonatal herpes.
Jones CA; Cunningham AL
Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
5. The challenge of developing a herpes simplex virus 2 vaccine.
Dropulic LK; Cohen JI
Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
[TBL] [Abstract][Full Text] [Related]
7. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
[TBL] [Abstract][Full Text] [Related]
8. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
9. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Jones CA; Cunningham AL
Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
[TBL] [Abstract][Full Text] [Related]
10. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.
Stanfield BA; Kousoulas KG; Fernandez A; Gershburg E
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452501
[TBL] [Abstract][Full Text] [Related]
11. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
13. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
Diaz FM; Knipe DM
Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Stanberry LR
Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
[TBL] [Abstract][Full Text] [Related]
15. Herpes. Vaccines for HSV.
Stanberry LR
Dermatol Clin; 1998 Oct; 16(4):811-6, xiv. PubMed ID: 9891686
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.
Prichard MN; Kaiwar R; Jackman WT; Quenelle DC; Collins DJ; Kern ER; Kemble GM; Spaete RR
Vaccine; 2005 Nov; 23(46-47):5424-31. PubMed ID: 15950327
[TBL] [Abstract][Full Text] [Related]
17. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?
Halford WP
Expert Rev Vaccines; 2014 Jun; 13(6):691-710. PubMed ID: 24837838
[TBL] [Abstract][Full Text] [Related]
18. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
Awasthi S; Shaw C; Friedman H
Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
